Nexavar and Hepatic encephalopathy - a phase IV clinical study of FDA data

Summary:

Hepatic encephalopathy is reported as a side effect among people who take Nexavar (sorafenib tosylate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Lasix, and have Hepatic neoplasm malignant.

The phase IV clinical study analyzes which people have Hepatic encephalopathy when taking Nexavar. It is created by eHealthMe based on reports of 23,142 people who have side effects when taking Nexavar from the FDA, and is updated regularly.

What is Nexavar?

Nexavar has active ingredients of sorafenib tosylate. It is often used in hepatocellular carcinoma. eHealthMe is studying from 23,250 Nexavar users. Check the latest studies of Nexavar.

What is Hepatic encephalopathy?

Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure) is found to be associated with 914 drugs and 1,259 conditions by eHealthMe. Check the latest studies of Hepatic encephalopathy.

On Jul, 16, 2026

23,142 people reported to have side effects when taking Nexavar.
Among them, 739 people (3.19%) have Hepatic encephalopathy.

Could Nexavar cause Hepatic encephalopathy?

Among these 739 people:

How long have people been on Nexavar when they have Hepatic encephalopathy? *

Click here to view more results

What is the gender of people who have Hepatic encephalopathy when taking Nexavar? *

Click here to view

What is the age of people who have Hepatic encephalopathy when taking Nexavar? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Nexavar and have Hepatic encephalopathy?

- Check whether Hepatic encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nexavar:

Nexavar (23,250 reports)

Hepatic encephalopathy treatments and more:

Hepatic encephalopathy (15,814 reports)

How severe was Hepatic encephalopathy and when was it recovered:

Hepatic encephalopathy in Nexavar

Expand to all the drugs that have ingredients of sorafenib tosylate:

Hepatic encephalopathy and drugs with ingredients of sorafenib tosylate (904 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Nexavar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (914 drugs)

Browse all the conditions that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (1,259 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sorafenib tosylate (the active ingredients of Nexavar) and Nexavar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.